Editas Medicine, Inc. logo

Editas Medicine, Inc.

NASDAQ:EDIT

Overview | Financials
Company Name Editas Medicine, Inc.
Symbol EDIT
Currency USD
Price 5.62
Market Cap 462,177,560
Dividend Yield 0%
52-week-range 4.91 - 11.91
Industry Biotechnology
Sector Healthcare
CEO Dr. Gilmore O'Neill
Website https://www.editasmedicine.com

An error occurred while fetching data.

About Editas Medicine, Inc.

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that

Related Stocks

Theravance Biopharma, Inc. logo

Theravance Biopharma, Inc.

TBPH

9.29 USD

Deciphera Pharmaceuticals, Inc. logo

Deciphera Pharmaceuticals, Inc.

DCPH

25.46 USD

Pulmonx Corporation logo

Pulmonx Corporation

LUNG

9 USD

Catalyst Pharmaceuticals, Inc. logo

Catalyst Pharmaceuticals, Inc.

CPRX

16.49 USD

IGM Biosciences, Inc. logo

IGM Biosciences, Inc.

IGMS

9.22 USD

Replimune Group, Inc. logo

Replimune Group, Inc.

REPL

6.44 USD

TG Therapeutics, Inc. logo

TG Therapeutics, Inc.

TGTX

16.48 USD

DocGo Inc. logo

DocGo Inc.

DCGO

3.08 USD

Financials

Numbers are in millions USD

Numbers are in millions USD